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Abstract
FKBP5 (FKBP51) is a glucocorticoid receptor (GR) binding protein, which acts 
as a co-chaperone of heat shock protein 90 (HSP90) and negatively regulates GR. 
Its association with mental disorders has been identified, but its function in disease 
development is largely unknown. Long-term potentiation (LTP) is a functional 
measurement of neuronal connection and communication, and is considered one of 
the major cellular mechanisms that underlies learning and memory, and is disrupted 
in many mental diseases. In this study, a reduction in LTP in Fkbp5 knockout (KO) 
mice was observed when compared to WT mice, which correlated with changes to 
the glutamatergic and GABAergic signaling pathways. The frequency of mEPSCs 
was decreased in KO hippocampus, indicating a decrease in excitatory synaptic 
activity. While no differences were found in levels of glutamate between KO and WT, 
a reduction was observed in the expression of excitatory glutamate receptors 
(NMDAR1, NMDAR2B and AMPAR), which initiate and maintain LTP. The 
expression of the inhibitory neurotransmitter GABA was found to be enhanced in 
Fkbp5 KO hippocampus. Further investigation suggested that increased expression 
of GAD65, but not GAD67, accounted for this increase. Additionally, a functional 
GABAergic alteration was observed in the form of increased mIPSC frequency in the 
KO hippocampus, indicating an increase in presynaptic GABA release. Our findings 
uncover a novel role for Fkbp5 in neuronal synaptic plasticity and highlight the value 
of Fkbp5 KO as a model for studying its role in neurological function and disease 
development.
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Introduction
FKBP5 (FK506-binding protein 51, also known as FKBP51) belongs to a 
subclass of immunophilin proteins and exhibits peptidyl-prolyl cis–trans isomerase 
(PPIase) activity crucial for protein folding (Schiene and Fischer 2000). It functions 
as a co-chaperone of heat shock protein 90 (HSP90) and forms a glucocorticoid 
receptor (GR) complex with additional components (Reynolds, Ruan et al. 1999, 
Westberry, Sadosky et al. 2006, Stechschulte and Sanchez 2011). Previous 
research revealed that FKBP5 is highly expressed in the hippocampus (Scharf, Liebl 
et al. 2011) and it appears to be essential for hypothalamic-pituitary-adrenal (HPA) 
axis function, including the physiological stress response that shapes 
neuroendocrine reactivity and coping behavior (Binder 2009, Costin, Wolen et al. 
2013). In humans, single nucleotide polymorphisms (SNPs) within the FKBP5 gene 
are associated with increased recurrence of depressive episodes and increased 
susceptibility to post-traumatic stress disorder (PTSD), bipolar disorder, major 
depressive disorder, and suicide attempts (Binder, Salyakina et al. 2004, Binder, 
Bradley et al. 2008, Lekman, Laje et al. 2008, Tatro, Everall et al. 2009, Willour, 
Chen et al. 2009, Costin, Wolen et al. 2013, Ellsworth, Moon et al. 2013, 
Szczepankiewicz, Leszczynska-Rodziewicz et al. 2014). FKBP5 has also been 
implicated in the development of addiction and PTSD-alcohol use disorder 
comorbidity (Xie, Kranzler et al. 2010, McClintick, Xuei et al. 2013, Levran, Peles et 
al. 2014), as well as alcohol consumption (Qiu, Luczak et al. 2016) and alcohol 
withdrawal severity (Huang, Schwandt et al. 2014). 
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The associations of FKBP5 with these conditions suggests a critical role in 
neuroadaptation following stress, alcohol, or other insults. Animal studies have 
revealed that Fkbp5 mRNA expression is increased in the hippocampus following the 
stress of chronic social defeat (Wagner, Marinescu et al. 2012) and increased in the 
paraventricular nucleus (PVN) and central amygdala (CeA) following restraint stress 
(Scharf, Liebl et al. 2011). Our studies have found that relative to WT mice, Fkbp5 
KO mice consume more alcohol and suffer more severe alcohol withdrawal as 
measured by handling-induced convulsions (HICs) following both acute and chronic 
alcohol exposure (Huang, Schwandt et al. 2014, Qiu, Luczak et al. 2016). The 
expression level of FKBP5 has been correlated with several mental illnesses (Ising, 
Depping et al. 2008, Lekman, Laje et al. 2008, Binder 2009, Levran, Peles et al. 
2014), and is responsive to stress, alcohol, and morphine (Treadwell and Singh 
2004, McClung, Nestler et al. 2005, Balsevich, Uribe et al. 2014). Even though 
elimination of Fkbp5 has been found to elicit some behavioral changes (Hartmann, 
Wagner et al. 2012), electrophysiological examination and molecular analyses are 
necessary to ascertain differences in neuronal function and neurotransmitter 
regulation, respectively. 
Long-term potentiation (LTP) is critical in learning and memory, and its 
dysfunction underlies many mental diseases. LTP is defined as an increase in 
postsynaptic responses lasting hours to days following a high-frequency activation of 
excitatory synapses (Bliss and Gardner-Medwin 1973, Bliss and Lomo 1973), and is 
thought to be the functional basis underlying memory formation (Bliss and 
Collingridge, 1993; Bliss et al., 2014). In addition to variations in LTP, differences in 
neurotransmitter activity, particularly the glutamatergic (Nakanishi 1994, Swanson, 
Bures et al. 2005, Gos, Gunther et al. 2009) and GABAergic (Saba, Bennett et al. 
  
5
2011) systems require investigation to understand brain function. A variety of NMDA 
receptor subunits have been identified: the ubiquitously expressed NR1 subunit; a 
family of four distinct NR2 subunits (A, B, C, and D); and two NR3 subunits 
(Moriyoshi, Masu et al. 1991, Sugihara, Moriyoshi et al. 1992, Das, Sasaki et al. 
1998). All NMDARs appear to function as heteromeric assemblies composed of 
multiple NR subunits (Das, Sasaki et al. 1998). NMDAR1 is necessary for plasticity 
in the CA1 region (McHugh, Blum et al. 1996, Tsien, Huerta et al. 1996). Deletion of 
NR2B is associated with impairment of LTP in hippocampus (Li, Erzurumlu et al. 
1994, Kutsuwada, Sakimura et al. 1996), conversely, overexpression of NR2B 
enhances LTP and has been shown to enhance learning and memory (Tang, 
Shimizu et al. 1999). In addition, activation of the GABAergic system, particularly 
enhanced GABA release and GABA receptor trafficking, contributes to alcohol 
consumption (Enoch 2008, Saba, Bennett et al. 2011) and other mental illnesses 
(Sajdyk, Johnson et al. 2008, Luscher, Shen et al. 2011, Abdallah, Jackowski et al. 
2015). GABA synthesis may also play a key role in maintaining a high level of GABA 
activity. However, these signaling systems have not previously been studied in 
Fkpb5 KO mice, and little is known about the overall impact of Fkbp5 on synaptic 
output, which may be crucial for understanding its role in disease development.
In this study we have examined LTP function in Fkbp5 KO and WT mice, and 
measured alterations in the GABAergic and glutamatergic systems. The levels of 
Glutamate and GABA were measured, and NMDA receptor expression levels and 
GABA synthesis enzymes were quantified. Behavioral differences were also 
measured.
Materials and Methods
Animals
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All experimental protocols were reviewed and approved by the Animal Care 
and Research Advisory Committee in the Institute of Laboratory Animal Sciences, 
Chinese Academy of Medical Sciences, and the Indiana University School of 
Medicine. The animals were maintained in facilities fully accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). Development of Fkbp5 knockout (Fkbp5 KO) mice was described in a 
previous publication (Yong, Yang et al. 2007). Fkbp5 KO and WT littermates were 
bred through heterozygous mating and were back crossed to C57BL/6J inbred mice 
for at least 5 generations.
Brain slice preparation for electrophysiological measurement
Brain slices for electrophysiology were prepared from WT and KO male mice 
at 8 weeks of age as described previously (Hou et al., 2006). In brief, mice were 
deeply anaesthetized and brains were rapidly removed from the skull and transferred 
into ice-cooled artificial cerebrospinal fluid (ACSF) (in mM: 125 NaCl, 2.5 KCl, 1.25 
NaH2PO4, 25 NaHCO3, 10 D-Glucose, 2.5 CaCl2, and 1.5 MgCl2) and saturated with 
95 % O2 and 5 % CO2 at pH 7.3. Transverse slices of 400 μm thickness containing 
the hippocampus were cut with a Vibratome (Leica, VT 1000 S, Germany), which 
was filled with cold ACSF. The prepared slices were incubated in oxygenated ACSF 
at room temperature for at least 1 hour before being transferred to a recording 
chamber and bubbled with oxygenated ACSF at 32 ± 1 ºC.
Recording Long term synaptic plasticity response
Field excitatory postsynaptic potential (fEPSP) population responses were 
evoked by stimulation in the radiatum with a bipolar electrode placed on the CA3 
area using acute brain slices (two slices per animal) prepared from WT (N=3) and 
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KO (N=3) male mice at 8 weeks of age; a total of 6 recordings from each genotype. 
Extracellular recording electrodes were filled with 2 M NaCl and placed in the 
stratum radiatum of CA1. Data were digitized at 3 kHz using an Axopatch 700B 
amplifier and analyzed with Clampfit 10.5 software. Single test pulses at a 
stimulation intensity that elicited 40% of a maximal response of fEPSP slope were 
delivered as the baseline level. The slices were stimulated with single test pulses 
every 30 s for at least 30 min followed by Theta-burst stimulation (TBS) and 60 min 
of test stimulation without changing intensity. All TBS contained 10 bursts at 200 ms 
inter-stimulation intervals, in which one burst consisted of four pulses of 100 Hz, 
repeated 3 times with 10 s inter-stimulation intervals. The time course of changes in 
the fEPSP slope was calculated in relation to the signals obtained during the last 10 
min prior to TBS (100%), normalizing all responses to this baseline and then 
averaging across experiments. The degree of LTP was expressed as a percentage 
of the original control level. All changes in long-term synaptic plasticity were 
evaluated by averaging the 10 responses at 51-60 min post-TBS and comparing 
these data to the 10 control signals during the 10 min prior to TBS. All data are 
presented as means ± SEM. Student’s t-test was performed for statistical evaluation 
of the data.
Analysis of L-glutamic acid content in hippocampus using LC–MS/MS
Both sides of hippocampi (10 mg) from WT (n=3) and KO (n=3) were 
homogenized with 800 μL of 80% acetonitrile (containing 0.2% formic acid and 5 mM 
ammonium formate) and further extracted by ultrasonication for 5 min. After vortex 
and centrifugation at 13,225 g for 10 min at room temperature, the supernatants 
were collected for L-glutamic acid measurement. Aliquots of 5 μL were injected onto 
the LC-MS/MS system. Liquid chromatography was performed with the LC system (I-
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class Acquity ultra performance liquid chromatography, Waters) including an 
autosampler and ultra-high performance binary pump. MS/MS detection was 
performed on an API 4500 QTRAP mass spectrometer (Applied Biosystems/MDS 
SCIEX) equipped with a heated electrospray ionization (ESI) source operated in the 
positive ionization mode. Nitrogen was used as the nebulizer and desolvation gases. 
Typical operating parameters were set as follows: curtain gas (CUR) 10, collision 
gas (CAD) medium, temperature 300 °C, ion source gas 1 (GS1) 45, ion source gas 
2 (GS2) 50, and electrospray voltage 5500 V. The ion transitions were m/z 
148.1→84.0 for L-glutamic acid (collision energy = 21 V). The peak areas of different 
concentrations of L-glutamic acid (0.008 ng/mL-20 ng/mL, Sigma-Aldrich, Saint 
Louis, MO, USA) analyzed by QTRAP 4500 were collected to establish standard 
curves and further calculate the concentrations of each analyte in real samples.
Western blotting analysis
Hippocampi were harvested on ice in lysis buffer (Beyotime, Jiangsu, China) 
with 1:10 volume of protease inhibitor (S8800, Sigma-Aldrich, Saint Louis, MO, USA) 
and 1:100 volume of phosphatase inhibitor cocktail (P0044, Sigma-Aldrich, Saint 
Louis, MO, USA). After centrifugation, the supernatants were collected and protein 
concentrations were determined using a BCA kit (Beyotime, Jiangsu, China). The 
samples were mixed with loading buffer and denatured. Proteins (40 μg each lane) 
were separated by 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels (Tanon 
equipment) and electrically transferred onto a nitrocellulose membrane (0.2 μm) (Pall 
Corporation, Ann Arbor, MI). Membranes were blocked prior to immunoblotting with 
primary antibodies at 4oC overnight. Blots were then incubated with HRP-conjugated 
secondary antibodies (1:5000, Santa Cruz, CA) and proteins were detected using 
ECL western blotting reagent kits. Signals were monitored by the Tanon 5500 
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Chemiluminescent Imaging System (Tanon, Shanghai, China) and quantified using 
TanonGis software (Tanon, Shanghai, China). Density values were normalized to 
GAPDH signal and provided as the mean ± SEM. Antibodies used in this study: anti-
AMPA (1:500), anti-NMDAR1 (1:500), anti-NMDAR2B (1:1000), anti-GAD65 (1:500), 
anti-GAD67 (1:500), and anti-GAT1 (1:1000) antibodies were purchased from 
Abcam (Cambridge, UK). HRP-conjugated anti-GAPDH (1:5000) was purchased 
from KangChen Bio-tech, Inc. (Shanghai, China).
Immunolabeling of brain slices
Immunohistochemical (IH) labeling of brain slices from male mice at 8 weeks of age 
of both WT (N =3) and KO (N = 3) were performed as previously described (Bin Qiu, 
2016). Anti-GABA (1:200) antibody was purchased from Abcam (Cambridge, UK). 
For immunofluorescence (IF), male mice at 8 weeks age of both WT (N =3) and KO 
(N = 3) genotypes were anesthetized with an i.p. injection of tribromoethanol (20 
mg/ml, 0.018 ml/g BW), and perfused transcardially with PBS (pH 7.4, 4oC) followed 
by 4% paraformaldehyde (pH 7.4, 4oC). The brains were isolated, embedded in 
OCT, and sectioned at 10 μm thickness using a cryostat microtome (Leica 
CM3050S, Germany). Slices were mounted on 3-aminopropyltriethoxysilane (APES) 
coated slides, blocked, and incubated with primary antibodies overnight at 4oC and 
secondary antibodies for 1h at 37oC. Nuclei were stained with DAPI mounting media 
(Zhongshan Goldenbridge Biotechnology, China). The fluorescence signal was 
captured using confocal laser scanning microscopy (Leica TCS LSI, Germany). The 
antibodies used in these experiments include rabbit anti-NMDAR1 (1:25), rabbit anti-
NMDAR2B (1:25), rabbit anti-AMPAR (1:25), rabbit anti-GABA, and Alexa Flour® 
488-conjugated goat anti-Rabbit IgG (1:500) from Abcam (Cambridge, UK). The 
optical density (AOD) of GABA was quantified by ImageJ.
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Recording of miniature excitatory postsynaptic currents
Miniature excitatory postsynaptic currents (mEPSCs) of CA1 pyramidal cells 
were recorded in whole cell mode using acute brain slices (two slices per animal) 
prepared from WT (N=4) and KO (N=4) male mice at 8 weeks of age as described 
above; a total of 8 recordings per genotype. The electrophysiological recordings 
were obtained under visual control by use of an Olympus microscope (Olympus 
BX50-WI, Olympus, Japan) and a 40x long-working distance objective (NA 0.8). 
Patch pipettes with 4-6 MΩ resistance were pulled from 110 mm long borosilicate 
glass capillaries (GB 150F-86-10, Sutter instrument, USA). The ion currents were 
recorded by an Axopatch 700B amplifier and pClamp10.6. Only cells that showed a 
high seal resistance (>1 GΩ) and a series resistance <25 MΩ were included. The 
series- and input-resistances were checked before and after the recordings in each 
experimental sequence. Cells were excluded if the input resistance or series 
resistance changed more than 15 % throughout the experiment. Signals were 
obtained at a holding potential of -70 mV. For pharmacological isolation of AMPA 
receptor-mediated mEPSCs, 1μM Tetradotoxin (TTX, the voltage-gated sodium 
channel blocker) and 100 μM picrotoxin (PTX, GABAA receptor antagonist) were 
added to the ACSF to abolish action potentials and inhibitory postsynaptic current 
events, respectively. The intracellular solution consisted of the following: (in mM) 140 
K-gluconate, 2 MgCl2, 8 KCl, 10 HEPES, 0.2 NaGTP, and 2 Na2ATP. The pH was 
adjusted to 7.3 with KOH. For each cell, at least 5 minutes of recording was 
obtained. For the detection of spontaneous events, the “threshold research” option 
was used and each event was checked. Data were analyzed off-line by using 
pClamp10.6 for event Frequency and Amplitude. Unpaired t-test was used for 
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statistical analysis. Results are presented as mean ± SEM, and significance was 
defined as p<0.05.
Recording of miniature inhibitory postsynaptic currents
Miniature inhibitory postsynaptic currents (mIPSCs) of CA1 pyramidal cells 
were recorded in whole cell mode using acute brain slices (two slices per animal) 
prepared from WT (N=4) and KO (N=4) male mice at 8 weeks of age as described 
above. The signal was obtained at a holding potential of -70 mV. For 
pharmacological isolation of GABAA receptor-mediated spontaneous inhibitory 
postsynaptic currents, 10nM glycine, 20 μM DNQX (AMPA receptor antagonist), 25 
μM D-AP-5 (NMDA receptor antagonist), and 0.5μM TTX were added to the ACSF. 
The intracellular solution consisted of the following: (in mM) 135 CsCl, 10 HEPES, 2 
MgCl2, 20 TEACl, and 10 EGTA. The pH was adjusted to 7.3 with CsOH with a 
pipette resistance of 4-5MΩ. The non-parametric Mann-Whitney U test was 
performed for mIPSC statistical analysis. Results are presented as mean ± SEM and 
p<0.05 was considered significant. Cumulative distribution plots of mIPSC 
amplitudes and inter-event intervals were compared using the Kolmogorov-Smirnov 
Goodness of Fit Test.
Saccharin and quinine consumption test and the forced swimming test (FST)
Saccharin and quinine intake was tested in adult male KO (N= 14) and WT (N= 21) 
mice. Animals were individually caged with free choice of water and 1.03% (W/V) 
saccharin. Fluid intake was recorded twice during the 1 week test (Pelz, Whitney et 
al. 1973). Forced swimming test was performed using 3-month-old male KO (N=12) 
and WT (N=12) mice. Animals were individually placed in a 2-Liter glass beaker filled 
with water (22 ± 1 °C) to a height of 15  cm, so that the mouse could neither touch the 
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bottom nor escape. The test lasted for 5 min and the time spent floating versus 
struggling was recorded. The ‘floating behavior’ (where the animal remains almost 
immobile and with its head above water) was used as a parameter to analyze 
behavioral differences.
Statistical analysis
Unless otherwise noted, all values are presented as mean ± standard error of 
the mean (SEM). Differences between two groups were compared by Student’s t-test 
with GraphPad Prism (GraphPad Software Inc., San Diego, CA). P values less than 
0.05 were considered to be significant.
Results
LTP is decreased in Fkbp5 KO hippocampus
Responses to drugs and stress often present with aberrations in LTP, which 
may indicate the activation of a common substrate, resulting in alterations of synaptic 
strength (Nestler 2001, Wolf 2003, Niehaus, Murali et al. 2010). To investigate 
whether elimination of the Fkbp5 gene produces dysfunctions in LTP, 
electrophysiological testing was carried out on brain slices of WT and Fkbp5 KO 
mice. Stimulation electrodes were placed in the CA3 region of the hippocampus, and 
recording electrodes were placed in CA1 (Figure 1A), producing a typical change in 
evoked responses following LTP. Field excitatory postsynaptic potentials (fEPSPs) 
were recorded in the hippocampi of both WT and KO mice (Figure 1B and 1C). 
Relative to WT, the fEPSP slope was significantly lower in KO following TBS 
stimulation (Figure 1D). The bar graphs summarize the differences in percentage of 
fEPSP slope before and after TBS (Figure 1E). The data indicate that KO mice 
display significant reductions in LTP.
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Decreased expression of glutamate receptors in Fkbp5 KO hippocampus
Classical synaptic LTP requires glutamate and NMDA receptor (NMDAR) 
activation, which drives increased AMPA receptor (AMPAR) expression in the 
postsynaptic membrane (Bashir, Bortolotto et al. 1993). NMDA receptor activation 
occurs when it binds with glutamate and glycine (or D-serine), allowing positively 
charged ions to flow through the cell membrane. To determine the source of the 
reduced LTP observed in KO, we first measured the glutamate level in the 
hippocampi of KO and WT mice. However, no differences of glutamate content, 
measured by L-glutamic acid, were observed (Figure 2A). Further analyses were 
conducted to determine whether the observed reductions in LTP are associated with 
alterations in excitatory glutamate receptors in Fkbp5 KO mice. Indeed, significant 
reductions in NMDAR1, NMDAR2B, and AMPAR protein expression in the 
hippocampus were identified in Fkbp5 KO mice via Western blot (Figure 2B-D). 
Concurrent results were evident in immunofluorescence (IF) labeling. The majority of 
neurons in the CA1 and DG sub-regions displayed an abundance of NMDAR1 
(Figure 2E), NMDAR2B (Figure 2F), and AMPAR (Figure 2G) expression in WT 
mice, while the expression of these proteins was considerably reduced in Fkbp5 KO 
mice (Figure 2E-G). These results suggest that the decreased LTP observed in 
Fkbp5 KO mice may be partially due to lower expression levels of excitatory 
glutamate receptors
Decreased frequency of mEPSCs in Fkbp5 KO mice
Given the lack of change in glutamate abundance coupled with decreased 
expression of glutamate receptors in Fkbp5 KO hippocampus, we next investigated 
the functional glutamatergic synapse alterations in KO hippocampus, particularly 
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those that might account for the observed attenuation of LTP. At a holding potential 
of -70 mV, AMPA receptor-mediated mEPSCs were monitored with the addition of 
pharmacological agents (1μM TTX, 100 μM PTX) (Figure 3A). Compared with WT 
mice, the mEPSC frequency was significantly lower in KO mice (WT: 2.31 ± 0.18 Hz; 
KO: 1.33 ± 0.15 Hz, p < 0.001, Unpaired t-test) (Figure 3B and 3C), but no 
differences were observed in mEPSC amplitude (WT: 18.89 ± 1.15 Hz; KO: 17.23 ± 
1.44 Hz, p= 0.3809, Unpaired t-test) (Figure 3D and 3E). A reduced mEPSC 
frequency is usually interpreted as a decrease in the presynaptic release probability, 
however this is not consistent with the similar glutamate content observed between 
the WT and KO. An alternative explanation for the lower mEPSC frequency 
observed in KO is a reduction in the number of functional synaptic sites, which is 
consistent with the decreased expression of glutamate receptors in KO. Moreover, 
the lack of difference in the amplitude of the mEPSCs between WT and KO indicates 
a lack of change in the activation of the postsynaptic glutamate receptors that are 
present. Taken together, the reduced LTP in KO is likely due to a decreased number 
of functional excitatory synaptic sites, but is not associated with a change in the 
activation of postsynaptic glutamate receptors.
Increased GABA level in Fkbp5 KO hippocampus
Normal central nervous system function requires maintaining a balance 
between neuronal excitation and inhibition. Because GABA is the major inhibitory 
transmitter in the CNS, we examined GABA in Fkbp5 KO mice via IHC labeling. An 
increase in GABA was detected in the KO hippocampus relative to WT (Figure 4A 
and 4B). The magnified CA1, CA2, CA3, and DG sub-regions also displayed these 
differences, which were quantified (Figures 4C). In line with the observed increase in 
KO hippocampal GABA level, KO mice exhibited an increase in the expression of 
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GAD65 (also known as glutamate decarboxylase 2), an enzyme that catalyzes the 
decarboxylation of glutamate to GABA (Figure 5A). In addition to GAD65, KO mice 
also appeared to possess a slightly higher expression of another enzyme, GAD67 
(also known as glutamate decarboxylase 1), although this difference did not reach 
statistical significance (Figure 5B). Likewise, no significant difference in GABA 
transporter GAT1 expression could be detected between KO and WT (Figure 5C). 
These results provide evidence in support of enhanced GABA production in the 
presynaptic terminal partially via increased GAD65 enzyme in Fkbp5 KO mice. 
Increased frequency of mIPSCs in Fkbp5 KO mice
Based on the observed increase in GABA level, we next investigated the 
functional GABAergic alterations present in KO hippocampus, to determine whether 
such alterations could account for the previously observed attenuation of LTP. 
Hippocampal slices obtained from animals at 8 weeks of age were assessed using 
whole cell recording techniques. At a holding potential of -70 mV, miniature IPSCs 
(mIPSCs) were detected as fast inward currents, which could be blocked by 
application of 10 μM bicuculline, a competitive GABAA receptor antagonist (Figure 
6A). This result indicated that the mIPSCs were mediated via GABAA receptor 
activation. Cumulative probability analysis revealed a significant reduction in mIPSC 
inter-event intervals, indicating an increased frequency of these signals in KO mice 
(11.5 ± 1.2 Hz) when compared to WT (8.2 ± 0.5 Hz, p<0.05, Kolmogorov-Smirnov 
(KS)) (Figure 6B and 6C). However, the amplitudes of the mIPSCs demonstrated no 
significant differences between the two groups (KO: 21.17 ± 1.35 pA; WT: 21.2 ±1.13 
pA, p= 0.99) (Figure 6D and 6E). The increased frequency of mIPSCs in Fkbp5 KO 
mice is consistent with increased GABAergic synaptic activity and could indicate a 
change in the probability of transmitter release. This is in agreement with the 
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observed increase in KO hippocampal GABA. The unchanged amplitude of mIPSCs 
suggests that postsynaptic function is apparently unaffected.
Fkbp5 KO male mice display behavior differences compared to WT mice
SNPs in the FKBP5 gene have been associated with PTSD, depression, 
anxiety, and bipolar disorder (Binder, Bradley et al. 2008, Willour, Chen et al. 2009, 
Tatro, Nguyen et al. 2010). Given these associations and the role of GABAergic 
signaling in these illnesses, it was important to examine behavioral differences 
between male WT and Fkbp5 KO mice. Depression-like behavior was assessed 
using an anhedonia test and the forced swim test (Porsolt, Le Pichon et al. 1977, 
Lucki 1997). When given free access to water and saccharin, KO male mice 
exhibited reduced total saccharin consumption via t-test ( p<0.01) (Figure 7A); and 
this difference was not due to differences in taste sense as measured by quinine 
intake (Figure 7B). These results indicate that Fkbp5 KO male mice display 
decreased anhedonic behavior. FST has been used to assess the effects of genetic 
modification on depressive behavior in animals (Porsolt et al., 1977) or the learned 
immobility to adapt successfully to the inescapable situation (Cryan and Mombereau, 
2004). Male KO mice spent significantly more time floating than WT by t-test (p = 
0.01) (Figure 7C).
Discussion
FKBP5 plays an important role in various mental illnesses, including PTSD, 
anxiety, depression, and addiction. It also has important effects on signaling 
pathways and neuron development. Its role in the homeostatic plasticity of the 
glutamatergic and GABAergic systems has not previously been explored. In the 
present study, we discovered that mice lacking Fkbp5 exhibit reduced LTP, 
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associated with decreased mEPSCs and increased GABAergic synaptic function in 
the hippocampus. Saccharin consumption and FST behaviors were found to be 
impacted in the KO male mice. Our findings uncover a role for Fkbp5 in neuronal 
synaptic plasticity and highlight the value of Fkbp5 KO as a model for studying 
neurological disease. 
It has been established that the induction of LTP in the CA1 area of the 
hippocampus requires glutamate and the activation of NMDA receptors located in 
the cell membrane of the postsynaptic neuron. NMDA influx triggers an increase in 
calcium entry, leading to activation of postsynaptic molecular pathways, and 
increased postsynaptic AMPAR density, which is responsible for a persistent 
increase in the postsynaptic response (Bliss & Collingridge, 1993). In this study, a 
reduction of LTP was observed in Fkbp5 KO mice, suggesting altered neural function 
in the Fkbp5 KO hippocampus. As no differences in glutamate abundance were 
observed between WT and KO, and a reduction in the expressions of excitatory 
receptors (NMDAR1, NMDAR2B, and AMPAR) were found in KO, we conclude that 
the synthesis of glutamate is not altered in the ablation of Fkbp5 , and that the 
reduced LTP may be partially due to reductions of NMDAR1 and NMDAR2B levels in 
the postsynaptic membrane. Western blotting and immunofluorescence data 
indicated that Fkbp5 KO affects the molecular expression of these receptors in 
hippocampus (Fig. 2), resulting in altered neuronal activity. In addition to NMDA 
receptors, AMPA receptors on the postsynaptic membrane are required to drive LTP 
(Isaac, Nicoll et al. 1995, Liao, Hessler et al. 1995). Consistent with our 
observations, the reduction of AMPAR in Fkbp5 KO may also contribute to reduced 
LTP. Moreover, a significant decrease in mEPSC frequency was observed in KO 
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mice. Reduced mEPSC frequency indicates either a decrease in the presynaptic 
release probability or a decreased number of functional synaptic sites. 
GABAergic activity also plays a fundamental role in the induction of LTP 
(Wigstrom and Gustafsson 1983). Previous research has demonstrated that 
increasing doses of the GABA-enhancing diazepam (Riss, Cloyd et al. 2008) inhibits 
LTP, indicating that GABAergic activity exerts a powerful influence over LTP 
(Levkovitz, Avignone et al. 1999). In the current study, increased GABA was 
observed in Fkbp5 KO hippocampus, potentially due to increased GABA synthesis. 
GABA is primarily synthesized from glutamate by GAD67 and GAD65, which are 
expressed in different amounts in cell bodies and axon terminals (Erlander, 
Tillakaratne et al. 1991). GAD67 immunoreactivity is expressed throughout the cell 
body and in synaptic terminals (Kaufman, Houser et al. 1991), and is a rapidly 
synthesized and utilized form of GAD, allowing on-site synthesis in response to 
cellular stimulation (Esclapez, Tillakaratne et al. 1994). In contrast, GAD65 is 
localized exclusively in the terminals and is reversibly bound to the membrane of 
synaptic vesicles, which may represent a depot of GAD that can be recruited upon 
intense stimulation (Kaufman, Houser et al. 1991, Soghomonian and Martin 1998), 
and plays a specific role in the control of synaptic GABA release (Pinal and Tobin 
1998). Indeed, we observed a significant increase in GAD65 expression and a 
slightly elevated level of GAD67 expression in KO hippocampus, which may account 
for the higher level of GABA observed in KO mice. The lack of a significant 
difference in GABA transporter (GAT1) expression suggests that reuptake of GABA 
is unaffected. The expression of GAD in brain regions of patients suffering from 
major depressive disorder (MDD) has been investigated previously, with mixed 
findings in the pre-frontal cortex (PFC), temporal cortex, and thalamus (Bielau, 
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Steiner et al. 2007, Gos, Steiner et al. 2012), but some consistent observations of 
increased density of GAD-IR cells in the entorhinal cortex and the hippocampus 
(Cheetham, Crompton et al. 1988, Gos, Gunther et al. 2009, Gos, Steiner et al. 
2012). In this regard, our results are consistent with human studies in the 
hippocampus. There are considerable data linking altered GABAergic activity with 
HPA axis function, in which Fkbp5 plays an important role as a GR regulator. Fkbp5 
is highly expressed in brain regions associated with stress response, and responds 
to stress itself (Scharf, Liebl et al. 2011, Qiu, Luczak et al. 2016). Similarly GAD 
mRNA expression is enhanced in several hypothalamic regions, such as the 
dorsomedial hypothalamus, medial preoptic area, and BST (Bowers, Cullinan et al. 
1998), following both acute and chronic stress exposure. GR is expressed in the 
GABAergic neurons of the anterior hypothalamic area and mediates corticosteroid-
induced plasticity (Shin, Han et al. 2011). Therefore it is presently unclear whether 
Fkbp5 affects GAD and GABA directly or indirectly (e.g., via GR). In GAD65 KO 
mice, reductions in synaptic GABA release are attributable to fewer vesicles being 
released (Tian et al. 1999). Thus, increased GABA may result from enhanced 
expression of GAD65 in Fkbp5 KO. This would be consistent with the high frequency 
of mIPSCs, indicating an increase in presynaptic GABA release. The lack of an 
effect on mIPSC amplitude in Fkbp5 KO suggests that postsynaptic function is 
essentially unaffected. Reductions in LTP can be mediated by an increase in 
presynaptic GABAergic interneurons, due to the increased frequency of mIPSCs 
(Levkovitz, Avignone et al. 1999). Thus, decreased glutamate receptors and 
increased GABA may account for the decreased LTP observed in Fkbp5 KO.
GABAergic transmission in the brain has been implicated in the 
pathophysiology of depressive disorder (Abdallah, Jackowski et al. 2015). GABA 
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exerts its major function through the GABA type A receptors (GABAARs), which 
inhibit the hyperarousal state and anxiety. Reductions in LTP might be the causal 
link between FKBP5 SNPs and many mental illnesses (Szymanska, Budziszewska 
et al. 2009, Tatro, Nguyen et al. 2010, Schmidt, Buell et al. 2015). Previous studies 
found decreased GABA concentrations in brain regions, such as dorsolateral PFC 
and occipital cortex (OCC) of patients with MDD (Rajkowska, O'Dwyer et al. 2007, 
Sanacora and Saricicek 2007, Maciag, Hughes et al. 2010). Recent findings demand 
more brain region-specific and a more complex models are needed to study this 
issue (Pehrson and Sanchez 2015). The limitations of human studies make it difficult 
to evaluate the brain region-specific expression of neurotransmitters and related 
enzymes, and argue for more animal model research to delineate the regional 
molecular mechanisms.
In the current study, both anhedonic behavior and FST were found to be 
impacted in the male KO mice at baseline. Previous research determined that 
although young Fkbp5 KO (10-16 week old) mice do not display general behavioral 
changes at baseline, they spend significantly less time immobile following restraint 
stress (Touma, Gassen et al. 2011), a behavior also observed in aged Fkbp5 KO 
(17-20 month old) mice with no stress (O'Leary, Dharia et al. 2011). However, we 
observed a genotype effect, with unstressed 3-month-old male KO mice spending an 
increased amount of time floating. This difference could be due to the stress 
treatment utilized. Although the predominant interpretation of FST is that immobility 
reflects hopelessness and negative mood (Porsolt et al., 1977), other interpretations 
are that this may only reflect the acute effect of antidepressants (Mann 2005), or the 
learned immobility to adapt successfully to the inescapable situation (Cryan and 
Mombereau, 2004). Our interpretation is that the FST difference may indicate a 
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difference in cognitive function (Molendijk and de Kloet 2015). More research is 
needed to understand Fkbp5 gene function and its effect on learning and memory.
Previous research has demonstrated that GABA and GABAR agonism 
enhances immobility, indicating that GABAergic functions play some role in the 
mechanism of this immobility (Nagatani, Sugihara et al. 1984, Nagatani, Yamamoto 
et al. 1987, Aley and Kulkarni 1989, Ferre, Fernandez Teruel et al. 1994). More 
recent research found increasing central GABAergic activity using various drugs 
results in a depressant-like activity, measured as an increase in the duration of 
immobility in the FST model of depression (El Zahaf and Salem Elhwuegi 2014). 
These observations are in line with those of Fkbp5 KO, with higher GABA and 
enhanced immobility. One limitation of the present study is not having directly tested 
the manipulation of GABAergic or glutamatergic systems to identify their association 
with behavior changes. The use of only male mice in the present study represents 
another limitation, as comparisons between the sexes may have enriched our 
understanding.
We conclude that FKBP5 plays a critical role in neuronal synaptic plasticity on 
both excitatory and inhibitory synapses in the hippocampus. Further research into 
how the elimination of Fkbp5 alters neuron development, gene expression, and 
behavior will provide insights into future treatment strategies for mental illness.
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13 Figure legends
14 Figure 1. Fkbp5 KO mice exhibit decreased LTP. 
15 (A) The anatomical placement of electrodes in the mouse hippocampus for LTP 
16 measurement. (B) The LTP (blue) responses of WT mice. (C) The LTP (red) 
17 responses of KO mice. (D) The time course of changes in fEPSP slope during LTP 
18 measurement. (E) The calculated changes and statistical analysis in fEPSP slope 
19 during LTP measurement. All changes in long-term synaptic plasticity were 
20 evaluated by averaging 10 responses at 51-60 minutes post- theta-burst stimulation 
21 (TBS) and normalizing these data to 10 control signals at 11-20 minutes prior to 
22 TBS. Comparisons were made using WT (N=3) and KO (N=3) male mice at 8 weeks 
23 of age ; a total of 6 recordings from each genotype. Student’s t-test was applied 
24 statistical significant analysis: **represents p < 0.01. 
25
26 Figure 2. Fkbp5 KO mice possess reduced glutamate receptor expression in 
27 the hippocampus.
28 (A) The content of L-glutamic acid in hippocampus detected using LC–MS/MS by 
29 comparing KO (N=3) and WT (N=3) male mice. (B, C, and D) The expression of 
30 NMDAR1, NMDAR2B, and AMPAR in WT and Fkbp5 KO mouse hippocampus were 
31 determined by Western blotting. Data are provided as the mean ± SEM. 
32 Comparisons were made by Student’s t-test: *represents p < 0.05; **represents p < 
33 0.01; NS represents no statistical significance. (E, F, and G) The localization and 
34 expression of NMDAR1, NMDAR2B, and AMPAR in CA1 and DG sub-regions from 
35 WT and KO hippocampus were detected by immunofluorescence. The images within 
36 the white rectangles show an enlarged view of the boxed regions. Bar = 100 μm.
37
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38 Figure 3. Decreased frequency of mEPSCs in Fkbp5 KO mice.
39 (A) Representative signals of AMPA receptor mediated mEPSC recorded at a 
40 holding potential of -70 mV. (B) Cumulative probability plots of the mEPSC intervals 
41 reveal a shift to the right in the KO curve. (C) The frequency of mEPSCs significantly 
42 decreased in KO (N=4) compared to WT (N=4). (D) The cumulative plots of the 
43 mEPSC amplitude reveal no differences between the two groups. (E) No significant 
44 differences could be detected between the mEPSC amplitudes of the two groups. 
45 Comparisons were made by Student’s t-test: *** represents p < 0.001; NS represents 
46 no statistical significance. 
47
48 Figure 4. Fkbp5 KO mice possess increased GABA level in hippocampus.
49 (A) The protein expression of GABA in hippocampus of WT (N=3) and (B) KO (N=3) 
50 mice demonstrated by IHC. (C) Comparison of GABA at representative sub-regions 
51 of the hippocampus demonstrate a higher level of GABA in the CA1, CA2, CA3, 
52 DG1, DG2, and DG3 sub-regions in KO relative to WT. The statistic analysis of the 
53 average optical density (AOD) of GABA level that was quantified by ImageJ, and the 
54 results were showed as fold change relative to WT. Data are provided as the mean ± 
55 SEM. Comparisons were made by Student’s t-test: *, **, and *** represent p < 0.05, 
56 p < 0.01 and p < 0.001.
57
58 Figure 5. GABA transporter expression in the brain
59 (A) The expression of GAD65, (B) GAD67, and (C) GAT1 in the hippocampus from 
60 WT (N=3) and KO (N=3) mice determined by Western blotting. Comparisons were 
61 made by Student’s t-test: * represents p<0.05,
62
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63 Figure 6. Increased frequency of mIPSCs in Fkbp5 KO mice.
64 (A) Representative mIPSC signals recorded at a holding potential of -70 mV in the 
65 presence of 0.5 μM TTX, 20μM CNQX, and 25μM D-AP5 (two top traces). 
66 Application of 10 μM bicuculline blocks all mIPSCs (two bottom traces) indicating 
67 that mIPSCs are mediated by activity from GABAA receptors. (B) Cumulative 
68 probability plots of the mIPSC intervals reveal a shift to the left in the KO curve. (C) 
69 The frequency of mIPSCs was significantly higher in KO (N=4) compared to WT 
70 (N=4). (D) The cumulative plots of the mIPSC amplitude reveal no differences 
71 between the two groups. (E) No significant differences could be detected between 
72 the mIPSC amplitudes of the two groups. Comparisons were made by Student’s t-
73 test: *represents p < 0.05; NS represents no statistical significance. 
74
75 Figure 7. Fkbp5 KO mice display anhedonic behavior. 
76 (A) Compared to WT male mice (N=21), Fkbp5 KO mice (N=14) exhibited a 
77 significant reduction in saccharin intake. (B) No significant differences in quinine 
78 intake were observed between Fkbp5 KO and WT male mice. (C). Male Fkbp5 KO 
79 mice (N=12) exhibited increased floating time in FST relative to WT (N=12). 
80 Comparisons were made by Student’s t-test: * and ** represent p < 0.05 and p < 
81 0.01, respectively.
82
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